ESMO 2023 - European Society of Medical Oncology Congress
Oct 20 - Oct 24, 2023 | MadridSpain
LARVOL is not affiliated with European Society of Medical Oncology Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 11 titles linked to Trials
Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]
ARTO (NCT03449719), randomized phase II trial testing stereotactic body radiotherapy and Abiraterone Acetate in Oligometastatic castrate-resistant prostate cancer patients
Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) – The AVETUXIRI Phase II study (NCT03608046).
Phase 1b/2 Open-label Study (NCT04073615) to Evaluate the Safety, Tolerability, and Efficacy of Rivoceranib plus Trifluridine/Tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer
Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial
Tumor-restricted delivery of an immune-therapeutic payload by modified macrophages for the treatment of Glioblastoma: the TEM-GBM STUDY (NCT03866109)
Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant Non-Small Cell Lung Cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208).
Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-concept study (NCT04554771)
PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914)
Results from a Phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)